68.16
2.85%
-2.00
CRISPR Therapeutics AG stock is currently priced at $68.16, with a 24-hour trading volume of 1.60M.
It has seen a -2.85% decreased in the last 24 hours and a -22.26% declined in the past month.
The chart indicates a potential bearish trend, as the stock is below the $70.19 pivot point. If it approaches the $67.53 support level, significant changes may occur.
CRISPR Therapeutics AG Stock (CRSP) Financials Data
CRISPR Therapeutics AG (CRSP) Revenue 2023
CRSP reported a revenue (TTM) of $170.10 million for the quarter ending June 30, 2023, a +1,207% rise year-over-year.
CRISPR Therapeutics AG (CRSP) Net Income 2023
CRSP net income (TTM) was -$153.61 million for the quarter ending December 31, 2023, a +76.37% increase year-over-year.
CRISPR Therapeutics AG (CRSP) Cash Flow 2023
CRSP recorded a free cash flow (TTM) of -$272.35 million for the quarter ending December 31, 2023, a +48.90% increase year-over-year.
CRISPR Therapeutics AG (CRSP) Earnings per Share 2023
CRSP earnings per share (TTM) was -$1.93 for the quarter ending December 31, 2023, a +76.94% growth year-over-year.
CRISPR Therapeutics AG Stock (CRSP) Insider Trading
Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
---|---|---|---|---|---|---|---|
Kulkarni Samarth | Chief Executive Officer |
Mar 15 '24 |
Option Exercise |
19.12 |
20,000 |
382,400 |
228,122 |
Kulkarni Samarth | Chief Executive Officer |
Mar 15 '24 |
Sale |
72.48 |
20,000 |
1,449,628 |
208,122 |
Prasad Raju | Chief Financial Officer |
Mar 15 '24 |
Sale |
72.69 |
3,524 |
256,160 |
6,476 |
Kulkarni Samarth | Chief Executive Officer |
Mar 12 '24 |
Sale |
74.44 |
4,583 |
341,159 |
208,122 |
KASINGER JAMES R. | General Counsel and Secretary |
Mar 12 '24 |
Sale |
74.44 |
1,146 |
85,308 |
61,174 |
Kulkarni Samarth | Chief Executive Officer |
Mar 11 '24 |
Sale |
78.26 |
9,802 |
767,105 |
203,705 |
KASINGER JAMES R. | General Counsel and Secretary |
Mar 11 '24 |
Sale |
78.26 |
2,801 |
219,206 |
60,070 |
Kulkarni Samarth | Chief Executive Officer |
Feb 20 '24 |
Sale |
79.67 |
6,370 |
507,498 |
194,257 |
KASINGER JAMES R. | General Counsel and Secretary |
Feb 20 '24 |
Sale |
79.67 |
1,913 |
152,409 |
57,371 |
Kulkarni Samarth | Chief Executive Officer |
Feb 15 '24 |
Option Exercise |
19.12 |
20,000 |
382,400 |
207,377 |
CRISPR Therapeutics AG Stock (CRSP) Latest News
bluebird (BLUE) Misses on Q4 Revenues, Provides Portfolio Updates
Zacks Investment Research
3 No-Brainer Healthcare Stocks to Buy Right Now for Less Than $1,000
The Motley Fool
CRISPR Therapeutics AG (CRSP) Sees a More Significant Dip Than Broader Market: Some Facts to Know
Zacks Investment Research
Vertex (VRTX) Continues to Diversify Beyond CF Franchise
Zacks Investment Research
Buying These Dirt-Cheap Stocks Could Be a Brilliant Move
The Motley Fool
Vertex (VRTX) Kidney Disease Drug to Enter Clinical Development
Zacks Investment Research
About CRISPR Therapeutics AG
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, which targets sickle cell disease and beta-thalassemia with an ex vivo approach whereby cells are harvested from a patient, treated with a CRISPR/Cas9-based therapeutic and reintroduced into the patient. The company is also developing CTX101, a donor-derived gene-edited allogeneic CAR-T therapy targeting CD19-positive malignancies. In addition, it is developing earlier stage allogeneic CAR-T programs targeting B-Cell maturation antigen and CD70; hemoglobinopathies to treat other diseases, including Hurler Syndrome and severe combined immunodeficiency disease; programs that are in preclinical development for indications, including glycogen storage disease Ia and hemophilia; and programs targeting diseases of organ systems outside the liver, such as Duchenne muscular dystrophy and cystic fibrosis. It has a collaboration agreement with Vertex Pharmaceuticals, Incorporated Vertex Pharmaceuticals (Europe) Limited to develop, manufacture, commercialize, sell, and use therapeutics. The company also has research collaboration agreements with Neon Therapeutics for developing neoantigen-based therapeutic vaccines and T cell therapies; Massachusetts General Hospital Cancer Center to develop T cell therapies for cancer; and with the ViaCyte, Inc. for designing allogeneic cell therapies derived from gene edited human stem cells for use in the treatment of diabetes type 1, diabetes type 2, and insulin dependent diabetes. CRISPR Therapeutics AG is headquartered in Zug, Switzerland.
Cap:
|
Volume (24h):